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Visceral fat accumulation plays an important role in the development of several metabolic 
disorders, such as type 2 diabetes, dyslipidemia, and hypertension.  New genetic loci that 
contribute to the development of type 2 diabetes have been identified by genome-wide 
association studies.  In order to examine the association of type 2 diabetes susceptibility loci 
and visceral fat accumulation, we genotyped 1279 Japanese subjects (556 men and 723 women), 
who underwent computed tomography (CT) for measurements of visceral fat area (VFA) and 
subcutaneous fat area (SFA) for the following single nucleotide polymorphisms (SNPs): 
NOTCH2 rs10923931, THADA rs7578597, PPARG rs1801282, ADAMTS9 rs4607103, 
IGF2BP2 rs1470579, VEGFA rs9472138, JAZF1 rs864745, CDKN2A/CDKN2B rs564398 and 
rs10811661, HHEX rs1111875 and rs5015480, TCF7L2 rs7901695, KCNQ1 rs2237892, 
KCNJ11 rs5215 and rs5219, EXT2 rs1113132, rs11037909, and rs3740878, MTNR1B 
rs10830963, DCD rs1153188, TSPAN8/LGR5 rs7961581, and FTO rs8050136 and rs9939609.  
None of the above SNPs were significantly associated with VFA.  The FTO rs8050136 and 
rs9939609 risk alleles exhibited significant associations with body mass index (BMI) (P = 
0.00088 and P = 0.0010, respectively) and SFA (P = 0.00013 and P = 0.00017, respectively).  
No other SNPs were significantly associated with BMI or SFA.  Our results suggest that 2 
SNPs in the FTO gene are associated with subcutaneous fat accumulation.  The contributions 
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of other SNPs are inconclusive because of a limitation of the sample power. 
 







Metabolic syndrome is defined by 4 conditions: visceral fat obesity, impaired glucose tolerance, 
dyslipiemia, and hypertension.1  Various adipocytokines secreted from adipocytes have been 
identified and shown to cause dyslipidemia, hypertension, and insulin resistance.2, 3  Previous 
studies on adipocytokines indicate that visceral fat obesity plays a central role in the 
development of metabolic syndrome.  The determination of visceral fat mass is performed in 
terms of waist circumference, waist-hip ratio, or visceral fat area (VFA).  Waist circumference 
and waist-hip ratio are commonly used because they are simple and convenient.  However, 
VFA measured using computed tomography (CT) is one of the most precise methods to assess 
fat distribution.1, 4, 5  There is an abundance of evidence showing that body fat distribution is 
influenced by genetic loci.6-8  Genome-wide association studies (GWAS) were conducted to 
identify the loci linked to waist circumference and waist-hip ratio in the Caucasian population.9, 
10  Among the reported loci, we have reported that the rs1558902 and rs1421085 genotypes of 
the fat mass- and obesity-associated gene (FTO) were significantly associated with VFA as well 
as with subcutaneous fat area (SFA) and body mass index (BMI).11 
GWAS and meta-analysis of GWAS have also identified metabolic syndrome 
trait-associated genetic variations, including obesity, type 2 diabetes, dyslipidemia, and 
hypertension.12  We have previously reported that among the single nucleotide polymorphisms 
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(SNPs) susceptible to obesity,13-15 rs7498665 in the SH2B adaptor protein 1 (SH2B1) gene was 
associated with VFA,16 and that among hypertension-susceptible SNPs,17, 18 CYP17A1 
rs1004467 and NT5C2 rs11191548 were significantly associated with both reduced VFA and 
SFA in women, indicating a genetic background to central obesity.19  Visceral fat obesity is 
also a risk factor for the development of type 2 diabetes.  Several studies have investigated the 
association of type 2 diabetes loci from GWAS with body fat and BMI.20-22  However, there are 
few reports of the association between type 2 diabetes susceptibility SNPs and visceral fat 
accumulation.21, 23, 24  Associations between type 2 diabetes susceptibility SNPs except those 
exited in the FTO gene and visceral fat mass determined by using more precise method, such as 
CT and magnetic resonance imaging (MRI), have not been elucidated yet.  Therefore, we 
investigated the association between type 2 diabetes susceptibility SNPs and fat distribution 
(VFA and SFA) as determined by CT. 
 
MATERIALS AND METHODS 
Study subjects 
In this study, we enrolled 1279 Japanese subjects from outpatient clinics as described 
previously.16, 19  These patients agreed to undergo CT testing (in the supine position) to 
determine the VFA and SFA values at the umbilical level (L4–L5).  Both VFA and SFA values 
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were calculated using the FatScan software program (N2system, Osaka, Japan).25  The clinical 
characteristics of the subjects are summarized in Table 1.  Metabolic syndrome and metabolic 
abnormalities were diagnosed according to the criteria released by the Japanese Committee for 
the Diagnostic Criteria of Metabolic Syndrome in April 2005.4, 5  Written informed consent 
was obtained from each subject, and the protocol was approved by the ethics committee of each 
institution and of Kyoto University. 
DNA extraction and SNP genotyping 
Genomic DNA was extracted using Genomix (Talent Srl, Trieste, Italy) from blood samples 
collected from each subject.  We selected 23 SNPs identified as susceptibility loci for type 2 
diabetes by GWAS26-33 and constructed Invader probes (Third Wave Technologies, Madison, WI, 
USA) for the following SNPs: notch 2 (NOTCH2) rs10923931, thyroid adenoma-associated 
(THADA) rs7578597, peroxisome proliferator-activated receptor γ (PPARG) rs1801282, ADAM 
metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9) rs4607103, insulin-like 
growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs1470579, vascular endothelial growth 
factor A (VEGFA) rs9472138, JAZF zinc finger 1 (JAZF1) rs864745, cyclin-dependent kinase 
inhibitor 2A and cyclin-dependent kinase inhibitor 2B (CDKN2A/CDKN2B) rs564398 and 
rs10811661, hematopoietically expressed homeobox (HHEX) rs1111875 and rs5015480, 
transcription factor 7-like 2 (TCF7L2) rs7901695, potassium voltage-gated channel, KQT-like 
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subfamily, member 1 (KCNQ1) rs2237892, potassium inwardly-rectifying channel, subfamily J, 
member 11 (KCNJ11) rs5215 and rs5219, exostosin 2 (EXT2) rs1113132, rs11037909, and 
rs3740878, melatonin receptor 1B (MTNR1B) rs10830963, dermcidin (DCD) rs1153188, 
TSPAN8 tetraspanin 8/leucine-rich repeat containing G protein-coupled receptor 5 
(TSPAN8/LGR5) rs7961581, and FTO rs8050136 and rs9939609.  The SNPs were genotyped 
using Invader assays as previously described.34  The success rate of these assays was >99.0%. 
Statistical analysis 
For the additive model, we coded the genotypes as 0, 1, or 2 depending on the number of copies 
of the risk alleles.  Risk alleles refer to the type 2 diabetes-associated alleles, according to 
previous reports.26-33  Multiple linear regression analyses were performed to test the 
independent effects of the risk alleles on BMI, VFA, and SFA by taking into account the effects 
of other variables (i.e., age and gender) that were assumed to be independent of the effect of 
each SNP.  The values of BMI, VFA, and SFA were logarithmically transformed before 
multiple linear regression analysis.  Odds ratios (ORs) and P-values adjusted for age, gender, 
and BMI were calculated using multiple logistic regression analysis with genotypes, age, gender, 
and log-transformed BMI as the independent variables.  The Hardy–Weinberg equilibrium was 
assessed using the χ2-test.35  All statistical analyses was performed using software R 
(http://www.r-project.org/).  P-values were corrected by Bonferroni adjustment and P < 0.0021 
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(0.05/23) was considered statistically significant. 
RESULTS 
The clinical characteristics and genotypes of the subjects are listed in Tables 1 and 2, 
respectively.  All SNPs remained in the Hardy–Weinberg equilibrium, except rs5215 and 
rs5219 in KCNJ11 (P = 0.03) and rs1153188 in DCD genes (P = 0.04).  The minor allele 
frequencies did not diverge from those reported in the HapMap database.  The BMI, VFA, and 
SFA values for each SNP genotype are presented in Table 3.  Multiple linear regression 
analyses of the anthropometric parameters with respect to the 23 SNPs analyzed are listed in 
Table 4.  Two SNPs (rs8050136 and rs9939609) in the FTO gene were significantly associated 
with BMI in an additive model (P = 0.00088 and 0.0010, respectively).  Since the results in 
Table 3 showed that the dominant model was the best-fit model, we analyzed the above 2 SNPs 
in the dominant model.  Significant associations of BMI were observed with rs8050136 (P = 
0.00052) and rs9939609 (P = 0.00061) in a dominant model. 
 There is no SNP associated with VFA.  Only SNPs (rs8050136 and rs9939609) in the 
FTO gene were marginally associated with VFA (P < 0.05).  Two SNPs in the FTO gene were 
significantly associated with SFA (P = 0.00013 at rs8050136 and P = 0.00017 at rs9939609), 
while all other SNPs did not associate with SFA.  BMI, VFA and SFA are known to be affected 
by gender; therefore, we compared SFA in men and women separately.  Associations between 
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FTO rs8050136 and rs9939609 SNPs and BMI were not significant in either men (P = 0.045 at 
rs8050136 and P = 0.048 at rs9939609) or women (P = 0.0064 at rs8050136 and P = 0.0075 at 
rs9939609) in an additive model.  Associations of FTO rs8050136 and rs9939609 SNPs with 
SFA were not significant in either men (P = 0.0066 at rs8050136 and P = 0.0069 at rs9939609) 
or women (P = 0.0058 at rs8050136 and P = 0.0079 at rs9939609) in an additive model.  This 
negative association is most likely due to the decrease in the number of each genotype. 
We conducted the power analysis of linear regression (additive model) with a 
significance level of 0.05, using age and gender as explanatory parameters.  The estimated 
effect sizes per allele (regression coefficients) for logarithmically transformed BMI, VFA and 
SFA were 0.010, 0.017 and, 0.028, respectively, assuming from the values of rs8050136 and 
rs9939609 (Table 3).  The power of our statistical test was calculated on the basis of these 
estimated effect sizes and by performing 10,000 simulations.  When the allele frequency was 
assumed to be 0.2, the power was estimated to be 0.71 for BMI, 0.25 for VFA and 0.81 for SFA; 
however, when the allele frequency was assumed to be 0.1, the respective powers were 
estimated to be 0.47, 0.16, and 0.56. 
 Finally, we examined the association of these SNPs with impaired glucose tolerance.  
Although the number of subjects with impaired glucose tolerance was relatively small (n = 353), 
we could replicate the association of rs10811661 in the CDKN2A/B gene (P = 0.049), 
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rs2237892 in the KCNQ1 gene (P = 0.00013), and rs1113132 in the EXT2 gene (P = 0.043) with 
impaired glucose tolerance (Table 5). 
 
DISCUSSION 
Obesity, especially visceral fat obesity, is an important risk factor for the development of 
metabolic syndromes, including type 2 diabetes.  Recent GWAS revealed the genetic 
susceptibility factors for type 2 diabetes.  The relationship between type 2 diabetes-associated 
SNPs and visceral fat obesity is of considerable interest.  CT-based analyses are more accurate 
for evaluating the association of SNPs with visceral fat mass than BMI, waist circumference, or 
dual energy X-ray absorptiometry (DEXA)-based abdominal fat mass analysis.4, 5  Therefore, 
we investigated the association of type 2 diabetes susceptibility SNPs with VFA and SFA.  We 
demonstrated that only SNPs in the FTO gene are associated with SFA and BMI, but not with 
VFA.  FTO rs8050136 has been shown to be marginally associated with visceral fat mass 
measured by MRI in Germany (P = 0.05)36 and rs9939609 with intra-abdominal adipose tissue 
estimated by DEXA in Danish (P = 4.7×10-3).37  SNP rs8050136 has been reported to be 
marginally associated with VFA measured by CT in African Americans (P = 0.05), but not in 
Hispanic Americans.38  Our study showed the weak association VFA and rs8050136 (P = 
0.043).  Although the measurements of visceral fat were different, rs8050136 would be 
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associated with visceral fat accumulation.  Since the simulation study showed the power of this 
study for VFA were relatively low (α = 0.16 to 0.35), large sample size would be necessary to 
confirm the association.  SNP rs8050136 has been reported to be marginally associated with 
SFA measured by CT in African Americans (P = 0.038) and in Hispanic Americans (P = 
0.019),38 indicating that rs8050136 would be related with SFA in various populations. 
Other type 2 diabetes susceptibility SNPs were not associated with BMI, VFA, or SFA.   
Pecioska et al. reported that among the type 2 diabetes loci (SLC30A8, CDKN2A/B, CDKAL1, 
IGF2BP2, HHEX, PPARG, KCNJ11, TCFL2 and FTO), only FTO rs8050136 was associated 
with BMI, fat mass index (fat mass/height/height), and waist circumference.21  Our results 
were in agreement with those reported by Pecioska et al.  T allele of rs2237892 in the KCNQ1 
gene was reported to be associated with increased waist circumference (P = 0.043).24  However, 
the subjects with T-allele had lower VFA in our study.  A lack of association of type 2 diabetes 
loci, and VFA and SFA may be due to the low power of this study.  The associations between 
SNPs and type 2 diabetes were adjusted for BMI, age, and gender.  Thus, SNPs associated with 
both obesity and type 2 diabetes would be excluded in the screening stage.  Indeed, FTO was 
first discovered as a susceptibility gene for type 2 diabetes in an analysis that was not adjusted 
for BMI; after adjustment for BMI, the effect on type 2 diabetes was abolished.39 
 Most risk factors for type 2 diabetes are believed to act through perturbation of insulin 
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secretion rather than through insulin action (insulin resistance).40  It is believed that CDKN2A 
and CDKN2B genes are involved in reducing β-cell mass, while MTNR1B, TCFL2, and KCNJ11 
genes may be involved in β-cell dysfunction.  Only the FTO gene can act through insulin 
resistance caused by obesity.  Our results, demonstrating no significant association of type 2 
diabetes susceptibility SNPs with VFA or SFA, except for SNPs in the FTO gene, confirm the 
above mechanism for the development of type 2 diabetes. 
 In summary, we showed that 2 SNPs (rs8050136 and rs9939609) in the FTO gene are 
significantly associated with SFA and BMI and that other SNPs susceptible for type 2 diabetes 
are not associated with fat distribution.  Our results suggest that only SNPs in the FTO gene 
are involved in the mechanism of insulin resistance. 
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Table 1  General characteristics of the subjects 
 Men Women Total 
n 556 723 1279 
Age (years) 49.4 ± 12.2 52.2 ± 11.3 51.0 ± 11.8 
BMI (kg m-2) 30.2 ± 6.1 28.1 ± 5.3 29.0 ± 5.8 
VFA (cm2) 155.3 ± 67.7 99.8 ± 53.6 123.9 ± 66.1 
SFA (cm2) 206.7 ± 108.6 241.6 ± 97.2 226.5 ± 103.7 
Waist circumference (cm) 97.5 ± 11.3 91.8 ± 10.3 94.2 ± 11.1 
    
Prevalence of metabolic disease    
  Dyslipidemia 293 (53%) 244 (34%) 537 (42%) 
  Hypertension 379 (68%) 452 (63%) 831 (65%) 
  Impaired fasting glucose 177 (32%) 176 (24%) 353 (28%) 
  Metabolic syndrome 248 (45%) 162 (22%) 410 (32%) 
Data are shown as mean ± s. d. 
















rs10923931 1 120,319,482 NOTCH2 T/G T 1/39/1239 0.02 0.23 
rs7578597 2 43,586,327 THADA T/C T 1248/30/1 0.99 0.07 
rs1801282 3 12,368,125 PPARG G/C C 0/60/1219 0.94 0.39 
rs4607103 3 64,686,944 ADAMTS9 T/C C 202/604/472 0.59 0.70 
rs1470579 3 187,011,774 IGF2BP2 A/C C 551/591/134 0.33 0.19 
rs9472138 6 43,919,740 VEGFA T/C T 10/224/1044 0.08 0.59 
rs864745 7 28,147,081 JAZF1 G/A A 54/402/823 0.79 0.58 
rs564398 9 22,019,547 CDKN2A/B G/A G 30/324/925 0.10 0.80 
rs10811661 9 22,124,094 CDKN2A/B T/C T 420/598/261 0.52 0.07 
rs1111875 10 94,452,862 HHEX T/C C 648/525/105 0.35 0.93 
rs5015480 10 94,455,539 HHEX T/C C 895/355/29 0.20 0.37 
rs7901695 10 114,744,078 TCF7L2 T/C C 1182/96/1 0.03 0.51 
rs2237892 11 2,796,327 KCNQ1 T/C C 187/633/458 0.64 0.18 
rs5215 11 17,365,206 KCNJ11 T/C C 540/554/184 0.34 0.03 
rs5219 11 17,366,148 KCNJ11 C/T T 541/554/184 0.35 0.03 
rs1113132 11 44,209,979 EXT2 G/C C 161/590/527 0.64 0.84 
rs11037909 11 44,212,190 EXT2 T/C T 525/589/165 0.64 0.99 
rs3740878 11 44,214,378 EXT2 A/G A 513/595/171 0.64 0.94 
rs10830963 11 92,348,358 MTNR1B C/G G 451/616/212 0.47 0.95 
rs1153188 12 53,385,263 DCD A/T A 1211/65/3 0.98 0.04 
rs7961581 12 69,949,369 TSPAN8/LGR5 T/C C 828/392/57 0.23 0.23 
rs8050136 16 52,373,776 FTO C/A A 769/443/65 0.18 0.91 
rs9939609 16 52,378,028 FTO T/A A 768/446/64 0.18 0.94 
Abbreviations: Chr, chromosome; HWE, Hardy–Weinberg equilibrium. 
Table 3  Mean BMI, VFA, and SFA for 23 type 2 diabetes-susceptible SNPs 
  BMI (kg m-2)  VFA (cm2)   SFA (cm2)  
 Nearby  Genotype   Genotype   Genotype  
SNP ID gene(s) 11 12 22 11 12 22 11 12 22 
rs10923931 NOTCH2 25.8 28.7 ± 6.0 29.0 ± 5.8 122.6 122.8 ± 57.8 124.0 ± 66.4 120.4 229.1 ± 113.6 226.5 ± 103.4 
rs7578597 THADA 29.0 ± 5.8 27.8 ± 4.7 33.2 123.7 ± 65.9 130.5 ± 71.9 235.8 226.5 ± 103.9 219.4 ± 96.2 385.6 
rs1801282 PPARG – 28.9 ± 5.6 29.0 ± 5.8 – 120.4 ± 82.0 124.1 ± 65.3 – 224.6 ± 92.0 226.5 ± 104.3 
rs4607103 ADAMTS9 29.3 ± 6.9 29.0 ± 5.5 28.9 ± 5.6 127.4 ± 67.2 122.0 ± 68.2 125.1 ± 63.0 234.4 ± 115.4 224.9 ± 99.4 225.1 ± 104.0 
rs1470579 IGF2BP2 29.0 ± 5.8 29.2 ± 5.9 28.1 ± 5.0 122.0 ± 66.6 127.0 ± 66.3 116.8 ± 60.4 230.3 ± 102.9 225.7 ± 104.3 215.2 ± 104.7 
rs9472138 VEGFA 31.4 ± 4.6 28.4 ± 4.8 29.1 ± 6.0 134.1 ± 67.8 123.3 ± 66.8 124.0 ± 66.0 274.1 ± 102.6 212.8 ± 84.3 229.0 ± 107.3 
rs864745 JAZF1 28.0 ± 5.6 29.3 ± 6.0 28.9 ± 5.7 131.7 ± 68.7 126.4 ± 66.2 122.2 ± 65.9 201.1 ± 96.7 230.6 ± 106.5 226.1 ± 102.7 
rs564398 CDKN2A/B 29.8 ± 4.9 28.8 ± 5.4 29.0 ± 6.0 133.3 ± 65.5 124.8 ± 65.9 123.3 ± 66.3 226.2 ± 105.0 225.0 ± 99.6 227.0 ± 105.2 
rs10811661 CDKN2A/B 29.2 ± 5.5 28.9 ± 6.0 28.9 ± 5.8 128.6 ± 67.7 121.5 ± 63.5 122.1 ± 69.3 231.6 ± 101.3 223.1 ± 104.9 225.7 ± 104.9 
rs1111875 HHEX 29.1 ± 5.7 28.9 ± 5.7 29.1 ± 6.7 125.0 ± 65.2 123.7 ± 68.0 117.9 ± 62.5 230.6 ± 103.6 222.6 ± 101.5 220.7 ± 115.5 
rs5015480 HHEX 29.0 ± 5.7 29.1 ± 6.2 28.2 ± 3.7 124.2 ± 65.1 124.3 ± 69.7 111.3 ± 52.6 228.3 ± 104.3 224.0 ± 104.0 198.6 ± 78.3 
rs7901695 TCF7L2 29.1 ± 5.8 28.3 ± 5.1 33.2 124.9 ± 66.1 111.2 ± 65.4 235.8 227.6 ± 104.0 211.2 ± 99.3 385.6 
rs2237892 KCNQ1 29.6 ± 6.5 29.1 ± 5.8 28.7 ± 5.4 120.5 ± 65.0 124.6 ± 65.2 124.5 ± 68.0 242.9 ± 117.7 225.0 ± 103.0 221.9 ± 98.2 
rs5215 KCNJ11  29.0 ± 5.6 29.1 ± 6.1 28.5 ± 5.2 122.6 ± 64.3 125.6 ± 68.7 122.6 ± 63.6 228.9 ± 106.1 228.0 ± 103.1 214.4 ± 98.1 
rs5219 KCNJ11 29.0 ± 5.7 29.1 ± 6.1 28.5 ± 5.2 122.7 ± 64.3 125.6 ± 68.7 122.6 ± 63.6 229.0 ± 106.1 228.0 ± 103.1 214.4 ± 98.1 
rs1113132 EXT2 28.9 ± 6.2 29.2 ± 6.0 28.8 ± 5.4 128.4 ± 66.8 127.9 ± 69.7 118.0 ± 61.3 226.5 ± 107.4 228.4 ± 104.2 224.2 ± 102.2 
rs11037909 EXT2 28.7 ± 5.4 29.3 ± 6.0 28.9 ± 6.1 118.0 ± 61.4 128.0 ± 69.7 128.3 ± 66.3 223.7 ± 101.9 229.2 ± 104.5 225.4 ± 107.0 
rs3740878 EXT2 28.7 ± 5.4 29.3 ± 6.0 28.9 ± 6.1 117.9 ± 61.7 128.0 ± 68.7 128.1 ±69.0 222.9 ± 101.9 230.2 ± 104.7 224.1 ± 106.0 
rs10830963 MTNR1B 29.2 ± 5.9 29.0 ± 5.9 28.8 ± 5.2 124.8 ± 66.8 123.4 ± 66.2 123.6 ± 64.6 227.7 ± 105.7 224.5 ± 103.1 229.6 ± 101.8 
rs1153188 DCD 29.0 ± 5.8 28.4 ± 5.1 32.1 ± 2.2 124.4 ± 66.4 112.8 ± 60.9 154.4 ± 33.5 227.0 ± 103.6 214.3 ± 107.4 253.7 ± 64.9 
rs7961581 TSPAN8/LGR5 28.8 ± 5.4 29.5 ± 6.6 28.2 ± 4.9 122.4 ± 63.6 127.3 ± 70.4 121.9 ± 72.8 225.3 ± 102.7 230.3 ± 107.8 215.1 ± 90.2 
rs8050136 FTO 28.5 ± 5.7 29.7 ± 5.8 29.8 ± 6.0 120.3 ± 65.1 129.7 ± 67.3 128.0 ± 68.2 219.0 ± 103.8 235.6 ± 99.0 252.6 ± 125.5 
rs9939609 FTO 28.5 ± 5.7 29.7 ± 5.8 29.8 ± 6.1 120.3 ± 65.2 129.6 ± 67.1 128.5 ± 68.6 219.2 ± 103.9 235.2 ± 98.9 253.9 ± 126.1 
Abbreviation: 11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.  Allele1 and allele2 of each SNP is indicated in Table 2. 
Table 4  Quantitative association results for known type 2 diabetes risk alleles with BMI, VFA, and SFA 
 Nearby  BMI   VFA   SFA  
SNP ID gene(s) β SE P-value β SE P-value β SE P-value 
rs10923931 NOTCH2 -0.007 0.012 0.53  0.026 0.037 0.49 -0.010 0.029 0.75 
rs7578597 THADA  0.017 0.013 0.20 -0.030 0.042 0.48 -0.019 0.033 0.57 
rs1801282 PPARG -0.002 0.010 0.84  0.038 0.032 0.23  0.003 0.025 0.90 
rs4607103 ADAMTS9 -0.001 0.003 0.74  0.004 0.010 0.67 -0.005 0.008 0.54 
rs1470579 IGF2BP2 -0.004 0.003 0.18 -0.005 0.010 0.66 -0.011 0.008 0.16 
rs9472138 VEGFA -0.006 0.005 0.25 -0.004 0.016 0.83 -0.013 0.013 0.33 
rs864745 JAZF1  0.000 0.004 0.96 -0.019 0.012 0.11  0.008 0.009 0.39 
rs564398 CDKN2A/B  0.001 0.004 0.85  0.004 0.013 0.75  0.003 0.010 0.78 
rs10811661 CDKN2A/B  0.004 0.003 0.22  0.015 0.009 0.12  0.012 0.007 0.12 
rs1111875 HHEX -0.003 0.003 0.33 -0.019 0.011 0.074 -0.017 0.008 0.047 
rs5015480 HHEX -0.003 0.004 0.49 -0.013 0.013 0.33 -0.016 0.010 0.12 
rs7901695 TCF7L2 -0.009 0.008 0.27 -0.037 0.025 0.14 -0.033 0.020 0.095 
rs2237892 KCNQ1 -0.006 0.003 0.053  0.003 0.010 0.73 -0.015 0.008 0.064 
rs5215 KCNJ11  -0.002 0.003 0.43  0.000 0.010 1.00 -0.010 0.008 0.21 
rs5219 KCNJ11 -0.003 0.003 0.39  0.000 0.010 0.97 -0.010 0.008 0.20 
rs1113132 EXT2 -0.002 0.003 0.56 -0.015 0.010 0.13 -0.004 0.008 0.66 
rs11037909 EXT2 -0.002 0.003 0.45 -0.016 0.010 0.11 -0.004 0.008 0.63 
rs3740878 EXT2 -0.003 0.003 0.40 -0.015 0.010 0.13 -0.005 0.008 0.56 
rs10830963 MTNR1B -0.003 0.003 0.30 -0.008 0.010 0.41  0.002 0.008 0.80 
rs1153188 DCD -0.001 0.009 0.88  0.019 0.028 0.50  0.019 0.022 0.40 
rs7961581 TSPAN8/LGR5  0.001 0.004 0.83  0.005 0.012 0.65  0.001 0.009 0.93 
rs8050136 FTO  0.012 0.004 0.00088  0.023 0.011 0.043  0.035 0.009 0.00013 
rs9939609 FTO  0.012 0.004 0.0010  0.024 0.011 0.035  0.034 0.009 0.00017 
Data were derived from a linear regression analysis.  BMI, VFA, and SFA were adjusted for age and gender, and log-transformed for the analysis. 
Table 5  Association of type 2 diabetes-associated loci alleles and impaired fasting plasma glucose 
  Genotype(11/12/22)   
SNP ID Nearby gene(s) Case (n = 353) Control (n = 926) P-value OR (95% CI) 
rs10923931 NOTCH2 0/8/345 1/31/894 0.34 0.67 (0.29 – 1.52) 
rs7578597 THADA 345/8/0 903/22/1 0.96 1.02 (0.45 – 2.29) 
rs1801282 PPARG 0/11/342 0/49/877 0.08 1.87 (0.92 – 3.78) 
rs4607103 ADAMTS9 56/170/127 146/434/345 0.72 0.97 (0.80 – 1.16) 
rs1470579 IGF2BP2 147/163/41 404/428/93 0.33 1.10 (0.91 – 1.35) 
rs9472138 VEGFA 3/67/283 7/157/761 0.17 1.24 (0.91 – 1.68) 
rs864745 JAZF1 13/109/231 41/293/592 0.48 1.09 (0.86 – 1.37) 
rs564398 CDKN2A/B 8/79/266 22/245/659 0.13 0.82 (0.63 – 1.06) 
rs10811661 CDKN2A/B 129/165/59 291/433/202 0.049 1.20 (1.00 – 1.44) 
rs1111875 HHEX 184/131/37 464/394/68 0.64 1.05 (0.86 – 1.28) 
rs5015480 HHEX 248/92/13 647/263/16 0.51 1.09 (0.85 – 1.40) 
rs7901695 TCF7L2 323/30/0 859/66/1 0.22 1.34 (0.84 – 2.14) 
rs2237892 KCNQ1 40/167/146 147/466/312 0.00013 1.47 (1.21 – 1.79) 
rs5215 KCNJ11  141/158/53 399/396/131 0.28 1.11 (0.92 – 1.33) 
rs5219 KCNJ11 142/158/53 399/396/131 0.29 1.10 (0.92 – 1.33) 
rs1113132 EXT2 39/156/157 122/434/370 0.043 1.22 (1.01 – 1.49) 
rs11037909 EXT2 156/155/42 369/434/123 0.067 1.20 (0.99 – 1.45) 
rs3740878 EXT2 152/159/42 361/436/129 0.051 1.21 (1.00 – 1.47) 
rs10830963 MTNR1B 120/174/59 331/442/153 0.51 1.06 (0.88 – 1.28) 
rs1153188 DCD 333/20/0 878/45/3 0.99 1.00 (0.59 – 1.69) 
rs7961581 TSPAN8/LGR5 233/105/14 595/287/43 0.47 0.92 (0.73 – 1.16) 
rs8050136 FTO 202/131/19 567/312/46 0.82 1.03 (0.82 – 1.28) 
rs9939609 FTO 202/132/19 566/314/45 0.75 1.04 (0.83 – 1.29) 
Data were derived from logistic regression analysis.  P-value and ORs were adjusted for age, gender, and BMI.  BMI was log-transformed for the analysis. 
